![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 49, 38445-38451, December 8, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,
¶, and
From the
Center for Cardiovascular Research,
Department of Internal Medicine and the ¶ Department of Molecular
Biology and Pharmacology, Washington University School of Medicine,
St. Louis, Missouri 63110-1010, and the § Department of
Cell Biology and Physiology, University of Pittsburgh School of
Medicine, Pittsburgh, PA 15261
Received for publication, April 13, 2000, and in revised form, August 7, 2000
| |
ABSTRACT |
|---|
|
|
|---|
The Niemann-Pick type C1 (NPC1) protein is a key
participant in intracellular trafficking of low density lipoprotein
cholesterol, but its role in regulation of sterol homeostasis is not
well understood. To characterize further the function of NPC1, we
generated stable Chinese hamster ovary (CHO) cell lines overexpressing
the human NPC1 protein (CHO/NPC1). NPC1 overexpression increases the
rate of trafficking of low density lipoprotein cholesterol to the
endoplasmic reticulum and the rate of delivery of endosomal cholesterol
to the plasma membrane (PM). CHO/NPC1 cells exhibit a 1.5-fold increase in total cellular cholesterol and up to a 2.9-fold increase in PM
cholesterol. This increase in PM cholesterol is closely paralleled by a
3-fold increase in de novo cholesterol synthesis.
Inhibition of cholesterol synthesis results in marked redistribution of
PM cholesterol to intracellular sites, suggesting an unsuspected role
for NPC1 in internalization of PM cholesterol. Despite elevated total
cellular cholesterol, CHO/NPC1 cells exhibit increased cholesterol synthesis, which may be attributable to both resistance to oxysterol suppression of sterol-regulated gene expression and to reduced endoplasmic reticulum cholesterol levels under basal conditions. Taken
together, these studies provide important new insights into the role of
NPC1 in the determination of the levels and distribution of cellular cholesterol.
Intracellular cholesterol sorting and transport pathways play an
important role in the physiologic utilization of lipoprotein-derived cholesterol. Low density lipoprotein
(LDL)1 and modified
lipoprotein particles are trafficked to lysosomes, where the
cholesteryl esters are hydrolyzed to free cholesterol (1). The bulk of
LDL cholesterol is mobilized from lysosomes to the plasma membrane (PM)
and subsequently cycles back to the endoplasmic reticulum (ER) (2).
Approximately one-third of the unesterified lysosomal cholesterol is
delivered directly to the ER via a PM-independent transport pathway
(3). Cholesterol levels in the ER regulate cellular cholesterol
homeostasis through a feedback regulatory mechanism that controls
de novo synthesis and cellular uptake of cholesterol. This
regulatory system principally involves membrane-bound transcription
factors known as sterol regulatory element-binding proteins (SREBPs)
(4). When cells are sterol-depleted, the NH2-terminal
regions of the SREBPs are released through a two-step proteolytic
cleavage and translocate to the nucleus to promote transcription of
multiple genes involved in cholesterol and fatty acid homeostasis. When
cells are replete with sterols, proteolytic cleavage of SREBPs is
prevented, resulting in attenuation of SREBP-dependent gene transcription.
The Niemann-Pick type C1 (NPC1) protein has been identified as a key
participant in the intracellular trafficking of LDL cholesterol. Cells
that harbor mutations in NPC1 accumulate cholesterol in lysosomes and
exhibit delayed sterol-regulated gene expression (5). The human
NPC1 gene and its murine ortholog have been identified by
positional cloning methods (6, 7). The 1278-amino acid human NPC1
protein has 13 predicted membrane-spanning domains (8), five of which
share sequence homology with the putative sterol-sensing domains of
3-hydroxy-3-methylglutaryl-coenzyme A reductase, SREBP
cleavage-activating protein (SCAP), and Patched. In normal cells, NPC1
is located in a vesicular compartment, which is LAMP-2-positive
and mannose-6-phosphate receptor-negative (9). When cells are treated
with hydrophobic amines to block intracellular cholesterol trafficking,
the NPC1 protein co-localizes with sequestered cholesterol in lysosomes
(9).
Although previous studies show that NPC1 is required for mobilization
of LDL cholesterol from endosomes to the PM (2, 10, 11) and for
delivery of PM cholesterol to the ER for esterification (3, 11), the
role of NPC1 in cholesterol homeostasis is not well understood. To
further characterize the function of NPC1, we generated stable Chinese
hamster ovary (CHO) cell lines that overexpress NPC1 and examined
intracellular trafficking of LDL cholesterol and regulation of cellular
sterol homeostasis. In these cell lines the NPC1 protein is expressed
in physiologically appropriate cellular compartments, as demonstrated
by immunofluorescence and by stimulation of cholesterol trafficking.
Overexpression of NPC1 is associated with abnormal regulation of
cellular cholesterol content and distribution. These results further
our understanding of the relationship between cholesterol trafficking
and cellular cholesterol homeostasis.
Materials--
Dulbecco's modified Eagle's medium, Ham's F-12
medium, fetal calf serum, glutamine, penicillin/streptomycin, and
LipofectAMINE Plus were obtained from Life Technologies, Inc.
Lipoprotein-deficient fetal calf serum was obtained from Cocalico Labs.
Cholesterol oxidase was obtained from Calbiochem. U18666A was obtained
from Biomol. Compactin, Plasmids--
The human NPC1 cDNA in pSPORT-NPC1 was
provided by J. Strauss (University of Pennsylvania). A Cell Lines--
CHO-K1 cells were obtained from ATCC (CRL-9618).
CT60 cells, a CHO cell line that harbors mutations in NPC1 and SCAP,
were provided by T. Y. Chang (Dartmouth College). M12 cells are
mutant CHO-K1 cells that contain a deletion of the NPC1
locus.2 To generate the
CHO/NPC1 cell lines, CHO-K1 cells were infected with retrovirus
prepared by transient transfection of 293GPG-packaging cells with the
Cell Culture and Preparation of Reconstituted LDL--
Cells
were maintained in monolayer culture at 37 °C with 5%
CO2. All CHO cell lines were maintained in medium A (1:1
Dulbecco's modified Eagle's medium:Ham's F-12, 5% (v/v) fetal calf
serum, 2 mM glutamine, 50 units/ml penicillin, 50 µg/ml
streptomycin). Medium B consists of medium A in which fetal calf serum
has been replaced with 5% (v/v) lipoprotein-deficient fetal calf
serum. Medium C consists of medium B plus 20 µM compactin
and 0.5 mM mevalonate. Compactin and mevalonate were
prepared as described (14). 293GPG cells were grown in Dulbecco's
modified Eagle's medium with 10% (v/v) fetal calf serum, 2 mM glutamine, 50 units/ml penicillin, 50 µg/ml
streptomycin, 2 µg/ml puromycin, 0.3 µg/ml G418, and 1 µg/ml
tetracycline. LDL labeled with [3H]cholesteryl linoleate
(CL) ([3H]CL-LDL) was prepared with a specific activity
of 17,000 cpm/nmol of total cholesteryl linoleate (15).
Western Blot Analysis--
Microsomal proteins were prepared as
described previously (16) and non-boiled samples were resolved on
SDS-polyacrylamide gel electrophoresis (7.5%) under reducing
conditions. The gels were transferred onto nitrocellulose (0.45 mm;
Schleicher & Schuell) with a semi-dry electroblotter (Owl Scientific).
Western blot analysis of NPC1 expression was performed using a rabbit
polyclonal antibody raised against human NPC1 (amino acids 1261-1278)
at a dilution of 1:1000 and a peroxidase-conjugated F(ab')2
fragment donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories)
at 0.04 µg/ml. Detection was performed using a commercially available reagent (Renaissance, DuPont NEN).
Immunocytochemical Staining of NPC1 and Filipin Staining--
On
day 0, CHO cell lines were plated at 0.7 × 104
cells/well on 12-mm glass coverslips in 24-well dishes in medium A. For
cells treated with U18666A, media was replaced 8-10 h after plating with U18666A (2 µg/ml) in medium A. On day 1, the cells were washed twice with PBS and fixed with 4% paraformaldehyde in PBS for 30 min.
For experiments with LysoSensor staining, cells were incubated with 5 µM LysoSensor Green DND-153 for 2 h before fixation
and staining. The cells were washed twice with PBS and stained (and permeabilized) with 50 µg/ml filipin in PBS/10% normal goat serum for 30 min. The cells were then stained for NPC1 using an
affinity-purified antibody to the human NPC1 COOH terminus (amino acids
1261-1278). The cells were incubated with a 1:250 dilution of the
LDL-stimulated Cholesterol Esterification Assay--
Cholesterol
esterification assays were performed as described by Goldstein et
al. (17). On day 0, CHO cell lines were seeded in triplicate
(2.5 × 104 cells/35-mm well) in medium A. On day 1, the cells were washed twice with PBS and refed medium B. On day 2, the
cells were fed medium B with 50 µg/ml LDL. On day 3, the cells were
pulsed with [3H]oleate for 2 h and washed three
times with Tris-buffered saline at 4 °C, and lipids were extracted
with hexane:isopropyl alcohol (3:2). A chromatography recovery standard
was added (30 µg cholesteryl oleate, 30 µg triolein, 0.0005 µCi
[14C]cholesteryl oleate), and the samples were dried
under nitrogen. The lipids were separated by TLC (PE SIL G plates,
Whatman) using heptane:ethyl ether:acetic acid (90:30:1) and visualized
with iodine. The [3H]cholesteryl oleate was quantified by
liquid scintillation counting in Ecoscint (National Diagnostics). After
lipid extraction, monolayers were incubated with 0.1 N
NaOH, and protein determination was performed using the MicroBCA assay
(Pierce). LDL-specific cholesterol esterification was determined by
subtracting esterification rates for non-LDL-fed cells from LDL-fed cells.
Cholesterol Efflux Assay--
On day 0, CHO, M12, and CHO/NPC1
cells were seeded in triplicate (5 × 104 cells/35-mm
well) in medium A. On day 2, the cells were washed three times with PBS
and refed medium B. On day 3, the cells were fed 20 µg/ml of
[3H]CL-LDL in medium B plus 20 µg/ml progesterone. On
day 4, the cells were washed three times with PBS and incubated with
medium B plus 2% CD for up to 2 h. Lipids were extracted from the
media (CH3Cl:methanol (2:1)) and the cells
(hexane:isopropyl alcohol (3:2)), a recovery standard was added (0.0005 µCi [14C]cholesteryl oleate for media lipid samples; 80 µg cholesterol, 30 µg cholesteryl oleate, and 0.0005 µCi
[14C]cholesteryl oleate for cellular lipid samples), and
lipids were dried under nitrogen. Lipids were extracted from media by
CH3Cl:methanol (2:1), and cellular lipids were separated by
TLC as described above using heptane:isopropyl ether:acetic acid
(60:40:4) as the solvent. [3H]Cholesterol was quantified
by scintillation counting. Protein determinations were performed using
the MicroBCA assay. The percent cholesterol efflux was determined as
the amount of [3H]cholesterol in the medium divided by
the sum of the [3H]cholesterol in medium plus the
[3H]cholesterol in the cell extract.
Cholesterol Oxidase Treatment--
Cholesterol oxidase treatment
was performed as described previously (3). On day 0, CHO, M12, and
CHO/NPC1 cell lines were seeded in triplicate (5 × 104 cells/35-mm well) in medium A. On day 2, the cells were
washed twice with PBS and refed medium B. On day 3, the cells were fed either medium B or medium C with 1 µCi
[3H]cholesterol/well. On day 4, each well was washed
three times with Tris-buffered saline plus 2 mg/ml bovine serum albumin
(Sigma) at 4 °C for 5 min on a shaker, and rapidly washed twice with
PBS at room temperature. The cells were fixed in 1% glutaraldehyde in
PBS for 10 min at room temperature and incubated with cholesterol oxidase (2 units/well) and sphingomyelinase (0.1 units/well) in Ham's
F-12 for 30 min at 37 °C. The cells were washed twice with PBS, and
lipids were extracted as described above. A chromatography recovery
standard was added (20 µg cholesterol, 40 µg cholestenone, 30 µg
cholesteryl oleate, 0.0005 µCi [14C]cholesteryl
oleate), and the samples were dried under nitrogen. TLC was performed
as above using heptane:ethyl ether:acetic acid (90:30:1) as the
solvent. [3H]Cholesterol, [3H]cholestenone,
and [3H]cholesteryl oleate were quantified as described
above. Protein determinations were performed on parallel wells plated
in triplicate using the MicroBCA assay.
Assay of de Novo Cholesterol Synthesis--
Metabolic labeling
of de novo-synthesized cholesterol was performed as
described previously (18). On day 0, CHO, M12, CT60, and CHO/NPC1 cells
were seeded in triplicate in (2.5 × 104 cells/35-mm
well) in medium A. On day 1, the cells were washed three times with PBS
and refed medium B. On day 2, the cells were washed three times with
PBS and refed medium B with 0.5 mM
[14C]acetate (25 dpm/pmol). After a 2-h incubation, the
cells were washed three times with Tris-buffered saline at 4 °C, and
lipids were extracted as described above. A chromatography recovery
standard was added (20 µg cholesterol, 30 µg cholesteryl oleate,
0.002 µCi [3H]cholesterol), and the samples were dried
under a stream of nitrogen. TLC and [14C]cholesterol
quantification was performed as described under "Cholesterol Oxidase
Treatment," and protein determination was performed using the
MicroBCA assay.
Luciferase Reporter Assay--
On day 0, CHO, CT60, and CHO/NPC1
cells were plated in duplicate (6 × 105 cells/60-mm
dish) in medium A. On day 1, the cells were co-transfected with 1.5 µg of pSyn SRE and 0.5 µg of pCMV In Vitro Cholesterol Esterification Assay--
The in
vitro esterification assay was performed as described by Lange and
Steck (19). Cells were trypsinized, pelleted, and washed in 0.25 M sucrose, 5 mM sodium phosphate, pH 7.5. Pelleted cells were resuspended in 0.1 M sucrose, 5 mM sodium phosphate, pH 7.5, and swelled on ice for 10 min.
The cells were homogenized with a Dounce homogenizer (100-200
strokes), centrifuged to remove large particles, and adjusted to 1 mM dithiothreitol and 1 mg/ml bovine serum albumin. The
esterification reaction was started by the addition of 25 µM [14C]oleoyl-CoA followed by incubation
for 2 h at 37 °C. After extraction with
CH3Cl:methanol (2:1) and addition of a recovery standard (40 µg cholesterol, 30 µg cholesteryl oleate, 0.002 µCi
[3H]cholesterol), lipids were dried under nitrogen.
Cholesteryl oleate was recovered by TLC and quantified as described
under "LDL-stimulated Cholesterol Esterification Assay." Protein
determinations were performed using the BCA assay.
Isolation of CHO Cell Lines Overexpressing NPC1--
To study the
function of NPC1, we used a retroviral expression system to establish
stable CHO cell lines that overexpress NPC1. The human NPC1 cDNA
was cloned into the
Immunofluorescence studies were performed to confirm the expression of
NPC1 in these cell lines and to establish that when overexpressed in
CHO cells, the human NPC1 protein distributes to appropriate cellular
compartments. We co-stained fixed, permeabilized cells with
affinity-purified antibody to the NPC1 COOH terminus and with filipin,
a fluorescent polyene antibiotic that specifically binds unesterified
cholesterol (22). In wild-type CHO cells under basal conditions (Fig.
2A), weak staining for NPC1
was observed in granular structures that have been identified in
previous studies as late endosomes (9). This staining was not observed
in controls with secondary antibody-staining alone (data not shown).
Filipin staining was observed in a Golgi-like pattern and at the cell periphery (Fig. 2B). NPC1-staining was not observed in the
NPC1-null, filipin-positive M12 cell line (Fig. 2, C and
D). In CHO/NPC1 cell lines, robust NPC1 staining was
observed in granular and reticular structures (Fig. 2E).
Filipin primarily stained the PM and granular structures in the
CHO/NPC1 cells (Fig. 2F). The intensity of filipin staining
exceeded that of parental CHO cells, suggesting that these cells have
increased cellular cholesterol content.
To show that overexpressed NPC1 is also appropriately localized in the
setting of pharmacologic block of cholesterol trafficking, CHO/NPC1
cells were incubated with U18666A. This hydrophobic amine inhibits
mobilization of lysosomal cholesterol and results in the NPC mutant
phenotype (10). U18666A-treated cells were co-stained with an antibody
for NPC1, filipin, and a LysoSensor probe that specifically stains
acidic organelles (23). After treatment with U18666A, there was a
decrease in the granular NPC1-staining pattern and appearance of
multiple, large, perinuclear vesicular structures whose periphery
stains intensely for NPC1 (Fig.
3A, see arrows).
Many of these structures are cholesterol-rich as demonstrated by
filipin staining (Fig. 3B) and co-stain with LysoSensor probe (Fig. 3C), consistent with a late endosomal or
lysosomal localization. This pattern of circumferential staining around cholesterol-containing vesicular structures after U18666A treatment is
similar to the staining we have observed in mutant cell lines that have
normal NPC1 expression but genetic blocks in the
cholesterol-trafficking pathway.3
Overexpressed NPC1 Affects Cellular Cholesterol
Trafficking--
To characterize the effects of NPC1 overexpression on
LDL cholesterol trafficking, we compared LDL-stimulated cholesterol esterification in wild-type CHO, M12, and CHO/NPC1 cell lines. In
normal cells, uptake of LDL cholesterol expands the cellular cholesterol pool and activates acyl-CoA:cholesterol
O-acyltransferase (ACAT), catalyzing the esterification of
both de novo-synthesized and LDL-derived cholesterol in the
ER (3). Cells were incubated in medium B, fed LDL 50 µg/ml overnight,
and pulsed for 2 h with [3H]oleate. Esterification
rates, as determined by incorporation of [3H]oleate into
[3H]cholesteryl oleate, are shown in Fig.
4 as a percentage of the rate observed
for wild-type CHO cells. As expected, M12 cells have severely impaired
LDL-stimulated cholesterol esterification rates (20% of wild-type CHO
cells). Overexpression of NPC1 results in up to a 60% increase in
esterification rates compared with wild-type CHO cells and up to an
8.1-fold increase compared with M12 cells. The observed esterification
rates correlated with the level of NPC1 expression by Western blotting,
suggesting a dose-dependent relationship between the amount
of NPC1 protein and the delivery of LDL cholesterol to
acyl-CoA:cholesterol O-acyltransferase.
We also examined the effect of NPC1 overexpression on the delivery of
endosomal cholesterol to the PM. CHO and CHO/NPC1 cells were incubated
with progesterone and [3H]CL-LDL for 24 h and
treated with 2% CD for up to 2 h, and the rates of cholesterol
efflux were measured during a progesterone wash-out phase. After a 2-h
incubation with CD, cholesterol efflux from the M12 cells was decreased
by 30% as compared with wild-type CHO cells (Fig.
5). NPC1 overexpression increased
cholesterol efflux in the NPC1-27 and NPC1-28 cell lines by 43 and
21%, respectively, as compared with wild-type CHO cells. These
findings are consistent with previous studies that support a role for
NPC1 in the mobilization of lysosomal cholesterol (2, 10, 11). Taken
together, the immunofluorescence, cholesterol esterification, and
cholesterol efflux studies provide evidence that the exogenously
expressed NPC1 in our stable cell lines is targeted to appropriate
cellular membranes and functions in the trafficking of LDL cholesterol in a biologically relevant manner.
NPC1 Overexpression Affects Cholesterol Homeostasis--
We
anticipated that increased trafficking of LDL cholesterol to the ER and
PM in the CHO/NPC1 cells might alter the partitioning of cellular
cholesterol between the PM and interior membrane compartments and/or
affect the size of cellular cholesterol pools. To study the potential
effect of NPC1 overexpression on cellular distribution of cholesterol,
cells were labeled with [3H]cholesterol and treated with
cholesterol oxidase, which oxidizes cholesterol to cholestenone.
Quantification of [3H]cholestenone (cholesterol in the
oxidase-accessible pool) and unesterified [3H]cholesterol
provides a measure of PM and intracellular cholesterol pools,
respectively (25). We performed these studies under conditions of
lipoprotein starvation in the presence and in the absence of compactin,
an inhibitor of de novo cholesterol synthesis. As compared with wild-type CHO cells, M12 cells grown in the absence of compactin demonstrated a modest reduction (26% decrease) in the cholesterol content of the oxidase-accessible (PM) pool (Fig.
6, black bars). This finding
is consistent with the defect in M12 cells in mobilization of endosomal
cholesterol to the PM. In contrast, NPC1-overexpressing cell lines
demonstrated a dose-dependent increase in PM cholesterol content (up to 2.9-fold) in the absence of compactin. Strikingly, growth of CHO/NPC1 cells in the presence of compactin (Fig. 6, gray bars) reduced PM cholesterol to levels below that of
wild-type CHO cells, whereas intracellular cholesterol levels were
increased up to 2.5-fold. As a percentage of the values for wild-type
CHO cells, total cellular cholesterol in CHO/NPC1 cells was increased (up to 1.5-fold) and did not significantly differ in the presence or
absence of compactin. Taken together, these findings suggest that the
increase in PM cholesterol (in the absence of compactin) in the
CHO/NPC1 cell lines is due primarily to de novo cholesterol synthesis. Moreover, the redistribution of cholesterol from the PM to
the cell interior in the setting of inhibition of de novo cholesterol synthesis implies a role for NPC1 in internalization of PM
cholesterol.
To examine the mechanism of the excess sterol accumulation in the PM of
CHO/NPC1 cells, we measured rates of de novo cholesterol biosynthesis. CHO, M12, and CHO/NPC1 cell lines were incubated in
medium B and pulsed with [14C]acetate, and incorporation
of [14C]acetate into [14C]cholesterol was
measured. As a control, we also assessed de novo synthesis
in CT60 cells, which are resistant to sterol suppression because of a
D443N SCAP mutation (26, 27) and, therefore, would be expected to show
increased cholesterol synthesis relative to wild-type CHO cells. The
rate of cholesterol synthesis in the M12 cells did not differ
significantly from wild-type CHO cells (Fig.
7). By comparison, the rate of
cholesterol synthesis in the NPC1-1 cells was 3-fold greater than that
of wild-type CHO cells. For both of the NPC1-overexpressing cell lines
studied, the rate of de novo synthesis (301% of CHO for
NPC1-1, 108% of CHO for NPC1-28) closely paralleled the increase in
PM cholesterol levels (286% of CHO for NPC1-1, 105% of CHO for
NPC1-28).
To determine whether up-regulation of de novo cholesterol
synthesis was mediated by altered sterol homeostatic mechanisms involving SREBPs, we compared the ability of 25-HC to suppress SRE-dependent gene transcription in CHO and CHO/NPC1 cells.
CT60 cells were included as a control, since they are known to be
sterol-resistant (26, 27). Cells were transfected with pCMV
ER cholesterol levels are thought to play a central role in cholesterol
homeostasis through regulation of SCAP/SREBP function (4). To determine
whether the perturbations of SCAP/SREBP function in CHO/NPC1 cells
resulted from alteration of ER cholesterol pools, we used an in
vitro cholesterol esterification assay to measure the ER
cholesterol content in CHO and CHO/NPC1 cells under various growth
conditions. Under conditions of lipoprotein starvation (the conditions
under which cholesterol distribution measurements and de
novo cholesterol synthesis assays were performed), ER cholesterol levels in the CHO/NPC1 cells were reduced 20% as compared with wild-type CHO cells (Fig. 9). The low ER
cholesterol content in these cells likely contributes to the increase
in de novo cholesterol synthesis, which was observed despite
increased total cellular cholesterol levels. As expected, under
conditions of lipoprotein starvation in the presence of compactin (the
conditions under which SRE-dependent gene transcription
assays and cholesterol distribution measurements were performed), the
ER cholesterol levels in CHO/NPC1 and wild-type CHO cells showed a
decline. Previous studies show that treatment with 25-HC promotes
marked influx of cholesterol into the ER and propose this as an
important mechanism of oxysterol-induced suppression of SCAP-mediated
SREBP proteolysis (28). The addition of 25-HC stimulated influx of
cholesterol into the ER of the CHO/NPC1 cells (5.1-fold increase),
resulting in ER cholesterol levels in the CHO/NPC1 cells (71.2 pm/hr/mg) exceeding that of wild-type CHO cells (42.3 pm/h/mg).
Thus, oxysterol-mediated influx of cholesterol into the ER is intact in
the CHO/NPC1 cells, suggesting the sterol-resistant phenotype results
from another mechanism.
In this study we examined the effect of NPC1 overexpression on
regulation of cellular cholesterol homeostasis. We generated stable
CHO/NPC1 cells and characterized these cell lines by examining the
subcellular distribution of NPC1 and by assessment of cholesterol trafficking. We demonstrate by immunofluorescence that the NPC1 protein
in the CHO/NPC1 cell lines distributes to appropriate cellular
locations. Consistent with previous studies, we show that under normal
conditions the NPC1 protein resides in granular cytosolic structures,
and after pharmacologic block of cholesterol trafficking, accumulates
in a cholesterol-rich endosomal compartment (9). Furthermore, we
demonstrate that in a dose-dependent manner, overexpression
of NPC1 stimulates intracellular cholesterol trafficking in pathways in
which NPC1 is known to participate, including the delivery of
LDL-derived cholesterol to acyl-CoA:cholesterol
O-acyltransferase and the mobilization of endosomal
cholesterol to the PM (2, 3, 10, 11). Based on these findings, we
conclude that the sterol-related phenotype of the CHO/NPC1 cells is due
to overexpression of functional NPC1 protein.
In the present study several observations indicate that cholesterol
homeostasis in NPC1-overexpressing cells is perturbed. First, CHO/NPC1
cells demonstrate a marked increase in PM cholesterol and total
cellular cholesterol levels. We show that de novo
cholesterol synthesis is responsible for the increase in PM cholesterol
because inhibition of cholesterol synthesis completely abrogates the
increase in PM cholesterol. Moreover, the increased rates of
cholesterol synthesis (3-fold) in the CHO/NPC1 cells closely parallel
the increase in the PM sterol content (2.9-fold). Second, under
conditions of cholesterol starvation, CHO/NPC1 cells exhibit a striking
redistribution of cholesterol from the PM to the cell interior. In the
absence of de novo cholesterol synthesis, PM cholesterol is
reduced to levels below that of wild-type CHO cells, even in the cell
line with the lowest level of NPC1 expression (NPC1-28). These
findings imply an unsuspected role for NPC1 in trafficking of PM
cholesterol to intracellular membranes. Third, ER cholesterol levels in
the CHO/NPC1 cells are decreased by 20% as compared with wild-type CHO
cells. Although the mechanism underlying this decrease is unclear, it
is possible that overexpression of NPC1 may adjust the set-point of the
ER cholesterol levels either by stimulating cholesterol trafficking or
altering the cholesterol content of specific cellular compartments
(28). Fourth, despite appropriate oxysterol stimulation of cholesterol
movement to the ER, CHO/NPC1 cells fail to effectively suppress SREBP cleavage.
What is the mechanism by which NPC1 overexpression disrupts normal
regulation of sterol homeostasis? The increase in cholesterol synthesis
in the CHO/NPC1 cells is inappropriate given their increased total
cellular cholesterol. Low basal ER cholesterol levels likely provide a
stimulus for SREBP proteolysis and thereby contribute to the increased
rate of de novo cholesterol synthesis. However, appropriate
25-HC-stimulated movement of cholesterol to the ER occurs in CHO/NPC1
cells, and this influx of cholesterol fails to suppress
SRE-dependent gene expression. It is possible that the ER
cholesterol in CHO/NPC1 cells is unavailable for regulation of SREBP
proteolysis. Alternatively, NPC1 may directly interfere with SCAP/SREBP
function. In a recent study, overexpression of the sterol-sensing
domain (SSD) of SCAP prevented suppression by sterols of SCAP/SREBP
movement to the Golgi (24). A model has been proposed in which the
SCAP/SREBP complex binds to an ER retention protein through an
interaction involving the SSD of SCAP. The overexpressed SCAP SSD
competes with the SCAP/SREBP complex for binding to the putative
retention protein, allowing the complex to move to the Golgi despite
the presence of sterols. Similarly, overexpression of the
SSD-containing NPC1 may interfere with sterol regulation of SCAP/SREBP
movement by competing with SCAP for binding to this putative retention
protein. Elucidation of the molecular function of NPC1, in general, and
of the SSD, in particular, will shed light on the role of this protein
in sterol homeostasis.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-hydroxypropylcyclodextrin (CD), filipin
complex, human LDL, mevalonic acid, oleoyl-CoA, and sphingomyelinase
were obtained from Sigma. LysoSensor Green DND-153 was obtained from Molecular Probes. Oleic acid, triolein, and cholesteryl oleate were obtained from Nu-Check Prep. Cholesterol, cholestenone, and 25-hydroxycholesterol (25-HC) were obtained from Steraloids.
[3H]Cholesterol (75 Ci/mmol),
N-[9,10-3H]oleic acid (5 Ci/mmol),
N-[cholesteryl-1,2,6,7-3H]linoleate
(84 Ci/mmol), [oleate-1-14C]cholesteryl oleate
(59.5 mCi/mmol), [1-14C]oleoyl-Co-A (50 mCi/mmol), and
[1,2-14C]acetic acid (54 mCi/mmol) were obtained from
PerkinElmer Life Sciences.
U3hNPC1
construct was created by polymerase chain reaction using pSPORT-NPC1 as
template and the following primers:
5'-GCTCTAGACTGCCATGACCGCTCGCGGCCTGGC-3' and
5'-CGGGATCCCAGGATGCCCTGCGAGAGGGC-3'. The 3.8-kilobase polymerase chain
reaction product was digested with XbaI and BamHI
and subcloned into the XbaI and BamHI cloning
sites of the
U3 retroviral construct (12). All polymerase chain
reaction-derived sequences were confirmed by ABI Prism automated
sequencing. The pSyn sterol regulatory element (SRE) plasmid was a gift
of R. Deckelbaum and T. Osborne (13). The pCMV
gal used as a
transfection control consists of the lacZ gene driven by a
cytomegalovirus promoter.
U3hNPC1 construct (12). The retrovirally infected cells were plated
at limiting dilution, and colonies were screened by Western blot
analysis of microsomal fractions for human NPC1 expression (described
under "Western Blot Analysis").
-NPC1 antibody in filipin/PBS/10% normal goat serum for 60 min on a
shaker at 37 °C followed by incubation with a donkey anti-rabbit Cy3
secondary antibody at 5 µg/ml filipin/PBS/10% normal goat serum for
40 min on a shaker at 37 °C. The coverslips were washed three times
with PBS, mounted (SlowFade, Molecular Probes), and examined by
fluorescence microscopy on a Zeiss Axiovert epifluorescence microscope.
The following filter sets (Chroma) were used: for filipin, excitation filter 360/40 nm, beamsplitter 400 nm, emission filter 460/50 nm; for
LysoSensor, excitation filter 470/40 nm, beamsplitter 500 nm, emission
filter 535/40 nm; for Cy3, excitation filter 535/50 nm, beamsplitter
565 nm, emission filter 590 nm.
gal. Four hours
post-transfection, the media was changed to medium C supplemented with
0-1.0 µg/ml 25-HC. On day 2, cells were harvested in reporter lysis
buffer (Promega), and luciferase and
-galactosidase assays were
performed in duplicate for each sample. The luciferase activity in the
transfected cells was normalized to
-galactosidase expression to
correct for transfection efficiency.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
U3 retroviral vector and transfected into
293GPG-packaging cells to generate high titer virus encoding NPC1 (12).
The virus was used to infect CHO cells at high multiplicity of
infection, and clonal cell lines were isolated by plating at limiting
dilution. The clones were screened for NPC1 expression by Western
blotting of microsomal proteins with an antibody to the COOH terminus
of NPC1 (amino acids 1261-1278) (Fig.
1). This antibody recognizes proteins of
220 and 170 kDa in wild-type CHO cells and detects no protein in M12
cells in which the NPC1 locus has been deleted.2 We
observe an identical pattern on Western blots using a previously characterized antibody to NPC1 residues 1256-1274 (data not shown) (20). The 220- and 170-kDa bands likely represent heterogeneously glycosylated NPC1 and have been observed by others (21). Because the
COOH termini of human and hamster NPC1 only share 78% identity from
residues 1261-1278, the NPC1 antibody demonstrates a preference for
recognition of human over endogenous CHO sequences (note the 8-fold
difference in amount of protein loaded in CHO versus
CHO/NPC1 and human normal skin fibroblasts (NSF)
lanes). Therefore, to estimate levels of transgene
expression, we compared NPC1 expression in the CHO/NPC1 cell lines with
the endogenous NPC1 expression in human NSF. Among the CHO/NPC1 cell
lines, expression of NPC1 varies over a 12-fold range, with
NPC1-1
NPC1-27 > NPC1-9 > NPC1-28. The lowest
expressing CHO/NPC1 cell line, NPC1-28, expressed human NPC1 at a
level 1.3-fold above NSF. The highest expressing CHO/NPC1 cell line,
NPC1-1, expressed human NPC1 at a level 15-fold above NSF.

View larger version (37K):
[in a new window]
Fig. 1.
NPC1 overexpression in CHO cell lines.
CHO cell lines overexpressing human NPC1 were screened for NPC1
expression. Microsomal proteins (CHO and M12 cell lines, 80 µg;
CHO/NPC1 cell lines and human NSF, 10 µg) were separated by
SDS-polyacrylamide gel electrophoresis and analyzed by Western blotting
using an antibody to the COOH terminus of NPC1, horseradish
peroxidase-coupled secondary antibody, and chemiluminescence.

View larger version (37K):
[in a new window]
Fig. 2.
Distribution of NPC1 in NPC1-overexpressing
CHO cells. Wild-type CHO (A and B), M12
(C and D) and NPC1-1 cells (E and
F) were plated in medium A and co-stained with an antibody
to the COOH terminus of NPC1 (A, C, and
E) and filipin 50 µg/ml (B, D, and
F). Cells were examined by immunofluorescence
microscopy.

View larger version (34K):
[in a new window]
Fig. 3.
Distribution of NPC1 in U18666A-treated
CHO/NPC1 cells. On day 0, CHO/NPC1 cells were plated in medium A
and incubated with 2 µg/ml U18666A. On day 1, cells were incubated
with 5 µM LysoSensor Green DND-153 for 2 h before
fixation and stained for NPC1 (A) and filipin
(B). Acidic organelles were visualized using the LysoSensor
probe (C). Cells were examined by immunofluorescence
microscopy.

View larger version (21K):
[in a new window]
Fig. 4.
Increased LDL-stimulated cholesterol
esterification in NPC1-overexpressing cell lines. Cells were
plated in triplicate in medium A (2.5 × 104
cells/35-mm well) and then grown in medium B for 48 h. The cells
were fed LDL (50 µg/ml) for 16 h and then pulsed for 2 h
with [3H]oleate. The rate of incorporation of
[3H]oleate into cholesteryl [3H]oleate was
determined by scintillation counting after lipid extraction and TLC and
normalized to total cellular protein. LDL-specific cholesterol
esterification was determined by subtracting esterification rates for
non-LDL-fed wells from LDL-fed wells. Esterification rates
(pmol/min/mg) were normalized to wild-type CHO cells. Values are
means ± S.E. and are representative two independent
experiments.

View larger version (19K):
[in a new window]
Fig. 5.
Increased delivery of cholesterol to the PM
in CHO/NPC1 cells. Cells were plated in triplicate in (5 × 104 cells/35-mm well) in medium A, then grown in medium B
for 24 h. The cells were incubated for 24 h with 20 µg/ml
of [3H]CL-LDL in medium B plus 20 µg/ml progesterone.
The following day the cells were washed with PBS and incubated with
medium B plus 2% CD for up to 2 h. [3H]Cholesterol
was extracted from the media, and rates of cholesterol efflux were
determined. Values are means ± S.E. and are representative of
four independent experiments.

View larger version (26K):
[in a new window]
Fig. 6.
Altered distribution of cholesterol in
NPC1-overexpressing cell lines. Cells were plated in triplicate
(5 × 104 cells/35-mm well) in medium A for 48 h.
The media was replaced with medium B or medium C, and the cells were
pulsed with [3H]cholesterol (1 µCi/well). The cells
were fixed and treated with cholesterol oxidase and sphingomyelinase,
and lipids were extracted and analyzed by TLC. Incorporation of
[3H]cholesterol into the PM cholesterol (A),
intracellular cholesterol (B), and total cellular
cholesterol (C) pools were determined in the absence
(black bars) and presence of compactin (gray
bars). Values are means ± S.E. and are representative of two
independent experiments.

View larger version (19K):
[in a new window]
Fig. 7.
CHO/NPC1 cells exhibit increased de
novo cholesterol synthesis. On day 0, cells were plated
in triplicate (2.5 × 104 cells/35-mm well) in medium
A. On day 1, the media was replaced with medium B. On day 2, the cells
were refed medium B and pulsed with 0.5 mM
[14C]acetate for 2 h. Lipids were extracted and
analyzed by TLC, and incorporation of [14C]acetate into
[14C]cholesterol was quantified. Values are means ± S.E. and are representative of two independent experiments.
gal and
the pSyn SRE vector, which contains three SREs from the
3-hydroxy-3-methylglutaryl-coenzyme A synthase gene linked to a
luciferase reporter. SRE-containing reporter constructs serve as an
indicator of the status of SREBP maturation (13, 18). The luciferase
activity in the transfected cells was normalized to
-galactosidase
expression to correct for transfection efficiency. As expected, CHO
cells responded to incubation with 25-HC by suppression of
SRE-dependent transcription at 0.25 µg/ml 25-HC, whereas
CT60 cells were resistant to suppression (Fig.
8). CHO/NPC1 cells also failed to
suppress to wild-type levels. Resistance to suppression in these cells
increased in a dose-dependent manner with increasing
oxysterol concentration, whereas resistance in CT60 cells diminished
with increasing oxysterol concentration. In four independent
experiments, the degree of resistance correlated with the level of NPC1
expression (NPC1-1 > NPC1-9 > NPC1-27). At the highest
25-HC concentration (1 µg/ml), CHO/NPC1 cells were more resistant
than CT60 cells.

View larger version (42K):
[in a new window]
Fig. 8.
NPC1 overexpression inhibits sterol
suppression of pSyn SRE expression. On day 0, CHO, CT60, and
CHO/NPC1 cells were plated in duplicate (6 × 105
cells/60-mm dish) in medium A. On day 1, the cells were co-transfected
with 1.5 µg of pSyn SRE and 0.5 µg of pCMV
gal. Four hours
post-transfection, the media was changed to medium C supplemented with
0-1.0 µg/ml 25-HC. On day 2, cells were harvested, and luciferase
and
-galactosidase assays were performed in duplicate. Luciferase
activity is normalized for
-galactosidase expression, and data are
expressed as mean % activity of 0 µg/ml 25-HC ±S.E. The results are
representative of four independent experiments.

View larger version (65K):
[in a new window]
Fig. 9.
Measurement of ER cholesterol pool in
CHO/NPC1 cells. CHO, CHO/NPC1, and CT60 cells were plated in
triplicate in medium A and grown to 50% confluence in 6-cm dishes. The
cells were then refed either medium B, medium C, or medium C plus 1 µg/ml 25-HC. After 24 h, the cells were homogenized, and the
extracts were incubated with [14C]oleoyl-CoA for 1 h
at 37 °C. Lipids were extracted, and incorporation of
[14C]oleoyl-CoA into [14C]cholesteryl
oleate was quantified by TLC. Black, hatched, and
gray bars depict measurements made under conditions of
lipoprotein starvation, lipoprotein starvation plus compactin, and
lipoprotein starvation plus compactin and 25-HC, respectively. Values
are means ± S.E. and are representative of three independent
experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENTS |
|---|
We thank Peter Pentchev for helpful discussions and the Ara Parseghian Medical Research Foundation for providing a forum for scientific discussions.
| |
FOOTNOTES |
|---|
* This work was supported by grants from the National Niemann-Pick Disease Foundation (to D. S. O.) and the National Science Foundation (to E. E. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Center for
Cardiovascular Research, Washington University School of Medicine, Box
8086, 660 S. Euclid Ave., St. Louis, MO 63110. Tel.: 314-362-8737; Fax:
314-362-0186; E-mail: dory@imgate.wustl.edu.
Published, JBC Papers in Press, August 29, 2000, DOI 10.1074/jbc.M003180200
2 E. E. Millard, K. Srivastava, L. M. Traub, J. E. Schaffer, and D. S. Ory, unpublished results.
3 A. Frolov, K. Srivastava, D. Daphna-Iken, L. M. Traub, J. E. Schaffer, and D. S. Ory, manuscript in preparation.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
LDL, low density
lipoprotein;
CL-LDL, cholesteryl linoleate LDL;
CD,
-hydroxypropylcyclodextrin;
CHO, Chinese hamster ovary;
ER, endoplasmic reticulum;
25-HC, 25-hydroxycholesterol;
NPC1, Niemann-Pick
type C1;
PBS, phosphate-buffered saline;
PM, plasma membrane;
SRE, sterol regulatory element;
SREBP, sterol regulatory element-binding
protein;
SCAP, SREBP cleavage-activating protein;
SSD, sterol-sensing
domain;
U18666A, 3-
-(2-diethylaminoethoxy)androst-5-en-17-one;
NSF, normal skin fibroblasts.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Brown, M. S., and Goldstein, J. L. (1983) Annu. Rev. Biochem. 52, 223-261 |
| 2. | Neufeld, E. B., Cooney, A. M., Pitha, J., Dawidowicz, E. A., Dwyer, N. K., Pentchev, P. G., and Blanchette-Mackie, E. J. (1996) J. Biol. Chem. 271, 21604-21613 |
| 3. | Underwood, K. W., Jacobs, N. L., Howley, A., and Liscum, L. (1998) J. Biol. Chem. 273, 4266-4274 |
| 4. | Brown, M. S., and Goldstein, J. L. (1997) Cell 89, 331-340 |
| 5. | Liscum, L., and Faust, J. R. (1987) J. Biol. Chem. 262, 17002-17008 |
| 6. | Carstea, E. D., Morris, J. A., Coleman, K. G., et al.. (1997) Science 277, 228-231 |
| 7. | Loftus, S. K., Morris, J. A., Carstea, E. D., Gu, J. Z., Cummings, C., Brown, A., Ellison, J., Ohno, K., Rosenfeld, M. A., Tagle, D. A., Pentchev, P. G., and Pavan, W. J. (1997) Science 277, 232-235 |
| 8. | Davies, J. P., and Ioannou, Y. A. (2000) J. Biol. Chem. 275, 24367-24374 |
| 9. | Neufeld, E. B., Wastney, M., Patel, S., Suresh, S., Cooney, A. M., Dwyer, N. K., Roff, C. F., Ohmo, K., Morris, J. A., Carstea, E. D., Incardoma, J. P., Strauss, J. F., III, Vanier, M. T., Patterson, M. C., Brady, R. O., Pentchev, P. G., and Blanchette-Mackie, E. J. (1999) J. Biol. Chem. 274, 9627-9635 |
| 10. | Liscum, L., and Faust, J. R. (1989) J. Biol. Chem. 264, 11796-11806 |
| 11. | Cruz, J. C., Sugii, S., Yu, C., and Chang, T. Y. (2000) J. Biol. Chem. 275, 4013-4021 |
| 12. | Ory, D. S., Neugeboren, B. A., and Mulligan, R. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 11400-11406 |
| 13. | Worgall, T. S., Sturley, S. L., Seo, T., Osborne, T. F., and Deckelbaum, R. J. (1998) J. Biol. Chem. 273, 25537-25540 |
| 14. | Brown, M. S., Dana, S. E., and Goldstein, J. L. (1973) Proc. Natl. Acad. Sci. U. S. A. 70, 2162-2166 |
| 15. | Krieger, M., Brown, M. S., Faust, J. R., and Goldstein, J. L. (1978) J. Biol. Chem. 253, 4093-4101 |
| 16. | Stuhlsatz-Krouper, S. M., Bennett, N. E., and Schaffer, J. E. (1998) J. Biol. Chem. 273, 28642-28650 |
| 17. | Goldstein, J. L., Basu, S. K., and Brown, M. S. (1983) Methods Enzymol. 98, 241-260 |
| 18. | Rawson, R., Cheng, D., Brown, M. S., and Goldstein, J. L. (1998) J. Biol. Chem. 273, 28261-28269 |
| 19. | Lange, Y., and Steck, T. L. (1997) J. Biol. Chem. 272, 13103-13108 |
| 20. | Patel, S. C., Suresh, S., Kumar, U., Hu, C. Y., Cooney, A., Blanchette-Mackie, E. J., Neufeld, E. B., Patel, R. C., Brady, R. O., Patel, Y. C., Pentchev, P. G., and Ong, W. I. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 1657-1662 |
| 21. | Watari, H., Blanchette-Mackie, E. J., Dwyer, N. K., Glick, J. M., Patel, S., Neufeld, E. B., Brady, R. O., Pentchev, P. G., and Strauss, J. F., III (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 805-810 |
| 22. | Pentchev, P. G., Comly, M. E., Kruth, H. S., Vanier, M. T., Wenger, D. A., Patel, S., and Brady, R. O. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 8247-8251 |
| 23. | Barasch, J., Kiss, B., Prince, A., Saiman, L., Gruenert, D., and Al-Awqti, Q. (1991) Nature 352, 70-73 |
| 24. | Yang, T., Goldstein, J. L., and Brown, M. S. (2000) J. Biol. Chem. 275, 29881-29886 |
| 25. | Slotte, J. P., Hedstrom, G., Rannstrom, S., and Ekman, S. (1989) Biochim. Biophys. Acta 985, 90-96 |
| 26. | Cadigan, K. M., Spillane, D. M., and Chang, T. Y. (1990) J. Cell Biol. 110, 295-308 |
| 27. | Hua, X., Nohturfft, Goldstein, J. L., and Brown, M. S. (1996) Cell 87, 415-426 |
| 28. | Lange, Y., Ye, J., Rigney, M., and Steck, T. L. (1999) J. Lipid Res. 40, 2264-2270 |
This article has been cited by other articles:
![]() |
M. E. Gelsthorpe, N. Baumann, E. Millard, S. E. Gale, S. J. Langmade, J. E. Schaffer, and D. S. Ory Niemann-Pick Type C1 I1061T Mutant Encodes a Functional Protein That Is Selected for Endoplasmic Reticulum-associated Degradation Due to Protein Misfolding J. Biol. Chem., March 28, 2008; 283(13): 8229 - 8236. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Listenberger, A. G. Ostermeyer-Fay, E. B. Goldberg, W. J. Brown, and D. A. Brown Adipocyte differentiation-related protein reduces the lipid droplet association of adipose triglyceride lipase and slows triacylglycerol turnover J. Lipid Res., December 1, 2007; 48(12): 2751 - 2761. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. White, D. Jiang, J. D. Burgess, I. R. Bederman, S. F. Previs, and T. J. Kelley Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis Am J Physiol Lung Cell Mol Physiol, February 1, 2007; 292(2): L476 - L486. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Langmade, S. E. Gale, A. Frolov, I. Mohri, K. Suzuki, S. H. Mellon, S. U. Walkley, D. F. Covey, J. E. Schaffer, and D. S. Ory Pregnane X receptor (PXR) activation: A mechanism for neuroprotection in a mouse model of Niemann-Pick C disease PNAS, September 12, 2006; 103(37): 13807 - 13812. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Kiss, Z. Ma, K. Nakada-Tsukui, E. Brugnera, G. Vassiliou, H. M. McBride, K. S. Ravichandran, and Y. L. Marcel The Lipoprotein Receptor-related Protein-1 (LRP) Adapter Protein GULP Mediates Trafficking of the LRP Ligand Prosaposin, Leading to Sphingolipid and Free Cholesterol Accumulation in Late Endosomes and Impaired Efflux J. Biol. Chem., April 28, 2006; 281(17): 12081 - 12092. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Maguire and J. W. Reagan Jr. Silencing of the mutant SCAP allele accounts for restoration of a normal phenotype in CT60 cells selected for NPC1 expression J. Lipid Res., September 1, 2005; 46(9): 1840 - 1848. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. E. Millard, S. E. Gale, N. Dudley, J. Zhang, J. E. Schaffer, and D. S. Ory The Sterol-sensing Domain of the Niemann-Pick C1 (NPC1) Protein Regulates Trafficking of Low Density Lipoprotein Cholesterol J. Biol. Chem., August 5, 2005; 280(31): 28581 - 28590. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Papanikolaou, A. Papafotika, C. Murphy, T. Papamarcaki, O. Tsolas, M. Drab, T. V. Kurzchalia, M. Kasper, and S. Christoforidis Cholesterol-dependent Lipid Assemblies Regulate the Activity of the Ecto-nucleotidase CD39 J. Biol. Chem., July 15, 2005; 280(28): 26406 - 26414. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Hoffman and J. P. Geibel Fluorescent imaging of Cl- in Amphiuma red blood cells: How the nuclear exclusion of Cl- affects the plasma membrane potential PNAS, January 18, 2005; 102(3): 921 - 926. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ohgami, D. C. Ko, M. Thomas, M. P. Scott, C. C. Y. Chang, and T.-Y. Chang Binding between the Niemann-Pick C1 protein and a photoactivatable cholesterol analog requires a functional sterol-sensing domain PNAS, August 24, 2004; 101(34): 12473 - 12478. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kishida, I. Kostetskii, Z. Zhang, F. Martinez, P. Liu, S. U. Walkley, N. K. Dwyer, E. J. Blanchette-Mackie, G. L. Radice, and J. F. Strauss III Targeted Mutation of the MLN64 START Domain Causes Only Modest Alterations in Cellular Sterol Metabolism J. Biol. Chem., April 30, 2004; 279(18): 19276 - 19285. [Abstract] [Full Text] [PDF] |
||||
![]() |
|